Myeloma

Interim report for the three months ended 31 March 2007

Published in Cancer Weekly, May 29th, 2007

The Board of Directors of TopoTarget A/S (Copenhagen Stock Exchange: TOPO) today adopted the company's interim report for the three months ended 31 March 2007.

During the three months period ended 31 March 2007, operating expenses amounted to DKK 55.0 million against DKK 45.5 million in the year-earlier period, primarily due to the establishment of Savene(tm) sales forces in Europe and the USA. The operating loss for the period was DKK 44.5 million, compared with DKK 38.5 million in the same period of last year. The company posted a loss before tax of DKK 42.6 million in the first three months of 2007 against a pre-tax loss of DKK 37.1 million in the same period of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry